Conjugate Vaccine Market

Conjugate vaccine is a combination of a weak antigen with a strong antigen so as to provide active immunization against immune system having a stronger response to the weak antigen. In a conjugate vaccine, the weak antigen is covalently attached to a strong antigen and triggers stronger immunological response to the weak antigen. The weak antigen is a polysaccharide that is attached to strong protein antigen.

Conjugate vaccines target several leading causes of vaccine-preventable deaths. Advantages of conjugate vaccines include their ability to elicit immunological memory and to reduce asymptomatic carriage of the bacteria, resulting in marked herd immunity. These vaccines offer immunization from different bacterial strains. For instance, on January 24, 2022 according to the Centers for Disease Control and Prevention (CDC) April 2019 data, pneumococcal conjugate vaccine (called PCV13) protects against 13 types of pneumococcal bacteria. Whereas in 2021, US FDA (Food and Drug Administration) licensed PCV15 and PCV20 for use in adults 18 years or older. Clinical trial data showed that PCV15 and PCV20 caused the body’s immune system to create antibodies, which helped fight the pneumococcal bacteria, similar to PCV13.

Market Dynamics

Increasing prevalence of pneumonia cases are expected to drive growth of the global conjugate vaccine market over the forecast period. For instance, in August 2021, National Center for Biotechnology Information, published a report on Community-Acquired Pneumonia, which reported that the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics. In the U.S., the annual incidence is 24.8 cases per 10,000 adults with higher rates as age increases, whereas the mortality rate is as high as 23% for patients admitted to the intensive care unit.

Increasing initiatives taken by the governments of countries to launch new vaccines are expected to drive growth of the global conjugate vaccine market over the forecast period. For instance, in October 2021, Union Health Minister (India), Dr. Mansukh Mandaviya, launched a nationwide expansion of Pneumococcal 13-valent Conjugate Vaccine (PCV) under the Universal Immunization Programme (UIP) as a part of Azadi ka Amrit Mahotsav. Whereas, on the other hand communication and awareness packages on PVC were also made available in India.

Key features of the study:                                          

• This report provides an in-depth analysis of the global conjugate vaccine market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022 – 2030), considering 2021, as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by key players
• It profiles key players in the global conjugate vaccine market based on following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include, Sanofi S.A, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline plc., Bharat Biotech, Serum institute of India Pvt. Ltd., Biological E. Limited, Bio-Med, Bavarian Nordic, CSL Limited, Novartis AG, Vaxcyte, GSBPL, Taj Pharmaceuticals Limited, and Bavarian Nordic
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
• The global conjugate vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global conjugate vaccine market

Detailed Segmentation:

• Global Conjugate Vaccine Market, By Product Type:
  • Monovalent Conjugate Vaccine
  • Multivalent Conjugate Vaccine
• Global Conjugate Vaccine Market, By Disease Indication:
  • Pneumococcal
  • Influenza
  • Meningococcal
  • Typhoid
• Global Conjugate Vaccine Market, By Pathogen Type:
  • Bacterial
  • Viral
• Global Conjugate Vaccine Market, By Patients Type:
  • Pediatric
  • Adults
• Global Conjugate Vaccine Market, By Region:
  • North America
    • By country
      • U.S.
      • Canada
  • Latin America
    • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • By Country
      • U.K.
      • Germany
      • Italy
      • Spain
      • France
      • Russia
      • Rest of Europe
  • Asia Pacific
    • By Country
      • Australia
      • India
      • China
      • Japan
      • ASEAN
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • By Country
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • By Country/Region
      • South Africa
      • Central Africa
      • North Africa
• Company Profiles
  • Sanofi S.A*
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Pfizer, Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Bharat Biotech.
  • Serum institute of India Pvt. Ltd.
  • Biological E. Limited
  • Bio-Med
  • Biological E Limited
  • CSL Limited
  • Novartis AG
  • Vaxcyte
  • GSBPL
  • Taj Pharmaceuticals Limited.
  • Bavarian Nordic

 “*” marked represents similar segmentation in other categories in the respective section.